Cargando…
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645960/ https://www.ncbi.nlm.nih.gov/pubmed/26262777 http://dx.doi.org/10.1097/QAI.0000000000000790 |
| _version_ | 1782400903795441664 |
|---|---|
| author | Walmsley, Sharon Baumgarten, Axel Berenguer, Juan Felizarta, Franco Florence, Eric Khuong-Josses, Marie-Aude Kilby, J. Michael Lutz, Thomas Podzamczer, Daniel Portilla, Joaquin Roth, Norman Wong, Deborah Granier, Catherine Wynne, Brian Pappa, Keith |
| author_facet | Walmsley, Sharon Baumgarten, Axel Berenguer, Juan Felizarta, Franco Florence, Eric Khuong-Josses, Marie-Aude Kilby, J. Michael Lutz, Thomas Podzamczer, Daniel Portilla, Joaquin Roth, Norman Wong, Deborah Granier, Catherine Wynne, Brian Pappa, Keith |
| author_sort | Walmsley, Sharon |
| collection | PubMed |
| description | The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/lamivudine arm and 63% in the efavirenz/tenofovir/emtricitabine arm maintained viral loads of <50 copies per milliliter through W144 (P = 0.01). Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 13 (3%); efavirenz/tenofovir/emtricitabine arm, 48 (11%)] through W144. No treatment-emergent integrase or nucleoside resistance was observed in dolutegravir + abacavir/lamivudine recipients through W144. |
| format | Online Article Text |
| id | pubmed-4645960 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | JAIDS Journal of Acquired Immune Deficiency Syndromes |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46459602015-11-30 Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial Walmsley, Sharon Baumgarten, Axel Berenguer, Juan Felizarta, Franco Florence, Eric Khuong-Josses, Marie-Aude Kilby, J. Michael Lutz, Thomas Podzamczer, Daniel Portilla, Joaquin Roth, Norman Wong, Deborah Granier, Catherine Wynne, Brian Pappa, Keith J Acquir Immune Defic Syndr Clinical Science The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/lamivudine arm and 63% in the efavirenz/tenofovir/emtricitabine arm maintained viral loads of <50 copies per milliliter through W144 (P = 0.01). Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 13 (3%); efavirenz/tenofovir/emtricitabine arm, 48 (11%)] through W144. No treatment-emergent integrase or nucleoside resistance was observed in dolutegravir + abacavir/lamivudine recipients through W144. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015-12-15 2015-11-13 /pmc/articles/PMC4645960/ /pubmed/26262777 http://dx.doi.org/10.1097/QAI.0000000000000790 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
| spellingShingle | Clinical Science Walmsley, Sharon Baumgarten, Axel Berenguer, Juan Felizarta, Franco Florence, Eric Khuong-Josses, Marie-Aude Kilby, J. Michael Lutz, Thomas Podzamczer, Daniel Portilla, Joaquin Roth, Norman Wong, Deborah Granier, Catherine Wynne, Brian Pappa, Keith Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial |
| title | Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial |
| title_full | Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial |
| title_fullStr | Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial |
| title_full_unstemmed | Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial |
| title_short | Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial |
| title_sort | brief report: dolutegravir plus abacavir/lamivudine for the treatment of hiv-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the single randomized clinical trial |
| topic | Clinical Science |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645960/ https://www.ncbi.nlm.nih.gov/pubmed/26262777 http://dx.doi.org/10.1097/QAI.0000000000000790 |
| work_keys_str_mv | AT walmsleysharon briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT baumgartenaxel briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT berenguerjuan briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT felizartafranco briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT florenceeric briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT khuongjossesmarieaude briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT kilbyjmichael briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT lutzthomas briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT podzamczerdaniel briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT portillajoaquin briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT rothnorman briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT wongdeborah briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT graniercatherine briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT wynnebrian briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial AT pappakeith briefreportdolutegravirplusabacavirlamivudineforthetreatmentofhiv1infectioninantiretroviraltherapynaivepatientsweek96andweek144resultsfromthesinglerandomizedclinicaltrial |